These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25287679)

  • 21. Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases.
    Potretzke TA; Tan BR; Doyle MB; Brunt EM; Heiken JP; Fowler KJ
    AJR Am J Roentgenol; 2016 Jul; 207(1):25-31. PubMed ID: 26866746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.
    Aslam A; Kamath A; Spieler B; Maschiocchi M; Sabottke CF; Chernyak V; Lewis SC
    Abdom Radiol (NY); 2021 Aug; 46(8):3565-3578. PubMed ID: 33856509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging features of subcentimeter hypointense nodules on gadoxetic acid-enhanced hepatobiliary phase MR imaging that progress to hypervascular hepatocellular carcinoma in patients with chronic liver disease.
    Jang KM; Kim SH; Kim YK; Choi D
    Acta Radiol; 2015 May; 56(5):526-35. PubMed ID: 24838304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LI-RADS
    Chernyak V; Tang A; Flusberg M; Papadatos D; Bijan B; Kono Y; Santillan C
    Abdom Radiol (NY); 2018 Jan; 43(1):82-100. PubMed ID: 28647768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.
    Ehman EC; Behr SC; Umetsu SE; Fidelman N; Yeh BM; Ferrell LD; Hope TA
    Abdom Radiol (NY); 2016 May; 41(5):963-9. PubMed ID: 27193793
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase?
    Kobi M; Paroder V; Flusberg M; Rozenblit AM; Chernyak V
    Clin Radiol; 2017 Jan; 72(1):55-62. PubMed ID: 27842889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliability, Validity, and Reader Acceptance of LI-RADS-An In-depth Analysis.
    Barth BK; Donati OF; Fischer MA; Ulbrich EJ; Karlo CA; Becker A; Seifert B; Reiner CS
    Acad Radiol; 2016 Sep; 23(9):1145-53. PubMed ID: 27174029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
    Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
    Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LI-RADS Version 2018 Ancillary Features at MRI.
    Cerny M; Chernyak V; Olivié D; Billiard JS; Murphy-Lavallée J; Kielar AZ; Elsayes KM; Bourque L; Hooker JC; Sirlin CB; Tang A
    Radiographics; 2018; 38(7):1973-2001. PubMed ID: 30289735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update.
    Granata V; Fusco R; Avallone A; Catalano O; Filice F; Leongito M; Palaia R; Izzo F; Petrillo A
    Infect Agent Cancer; 2017; 12():23. PubMed ID: 28465718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS).
    Chernyak V; Fowler KJ; Heiken JP; Sirlin CB
    J Magn Reson Imaging; 2019 May; 49(5):1236-1252. PubMed ID: 30609194
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatobiliary phase hypointensity on gadobenate dimeglumine-enhanced magnetic resonance imaging may improve the diagnosis of hepatocellular carcinoma.
    Li Y; Chen J; Weng S; Yan C; Ye R; Zhu Y; Wen L; Cao D; Hong J
    Ann Transl Med; 2021 Jan; 9(1):55. PubMed ID: 33553348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gadoxetate disodium-enhanced MR imaging: differentiation between early-enhancing non-tumorous lesions and hypervascular hepatocellular carcinomas.
    Goshima S; Kanematsu M; Watanabe H; Kondo H; Mizuno N; Kawada H; Shiratori Y; Onozuka M; Moriyama N; Bae KT
    Eur J Radiol; 2011 Aug; 79(2):e108-12. PubMed ID: 21592707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classifying CT/MR findings in patients with suspicion of hepatocellular carcinoma: Comparison of liver imaging reporting and data system and criteria-free Likert scale reporting models.
    Zhang YD; Zhu FP; Xu X; Wang Q; Wu CJ; Liu XS; Shi HB
    J Magn Reson Imaging; 2016 Feb; 43(2):373-83. PubMed ID: 26119393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver.
    Kim JI; Lee JM; Choi JY; Kim YK; Kim SH; Lee JY; Han JK; Choi BI
    Invest Radiol; 2008 Mar; 43(3):202-10. PubMed ID: 18301317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pitfalls and problems to be solved in the diagnostic CT/MRI Liver Imaging Reporting and Data System (LI-RADS).
    Kim YY; Choi JY; Sirlin CB; An C; Kim MJ
    Eur Radiol; 2019 Mar; 29(3):1124-1132. PubMed ID: 30116960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study.
    Fowler KJ; Tang A; Santillan C; Bhargavan-Chatfield M; Heiken J; Jha RC; Weinreb J; Hussain H; Mitchell DG; Bashir MR; Costa EAC; Cunha GM; Coombs L; Wolfson T; Gamst AC; Brancatelli G; Yeh B; Sirlin CB
    Radiology; 2018 Jan; 286(1):173-185. PubMed ID: 29091751
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
    Lee MH; Kim SH; Park MJ; Park CK; Rhim H
    AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of the transitional phase at gadoxetate disodium-enhanced hepatic MRI for the diagnosis of hepatocellular carcinoma: preliminary results.
    Nakamura Y; Toyota N; Date S; Oda S; Namimoto T; Yamashita Y; Beppu T; Awai K
    J Comput Assist Tomogr; 2011; 35(6):723-7. PubMed ID: 22082543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.